Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Relmada doses 25% of subjects in Phase ll trial of dextromethadone

Relmada is investigating REL-1017 for major depressive disorder. Credit: Gloria Williams.

Go Top